PYC Therapeutics Limited announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) in support of its lead drug candidate known as VP-001. The FDA has a period of 30 days to review an IND application. In the event the IND is accepted, VP-001 will be the first investigational drug candidate with the potential to modify the course of Retinitis Pigmentosa type 11 to progress into clinical trials.